Geographic Atrophy—Or Is It?

Overview

Intravitreal complement inhibitors have been approved for treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD), showing efficacy in slowing disease progression. Accurate identification of GA is crucial, as misdiagnosis can lead to inappropriate treatment.

Background

Geographic atrophy is a significant cause of vision loss, affecting over 1 million people in the U.S. and millions worldwide. With the advent of new treatments, understanding the nuances of GA diagnosis is essential for optimizing patient outcomes. Misidentification of GA can lead to delays in appropriate therapy, underscoring the importance of accurate diagnostic methods.

Data Highlights

No numerical data provided in the article.

Key Findings

• Two intravitreal complement inhibitors, pegcetacoplan and avacincaptad pegol, are approved for GA secondary to AMD.
• Both treatments have shown to slow GA progression with monthly or every-other-month administration.
• OCT and fundus autofluorescence are critical in accurately diagnosing GA and differentiating it from other conditions.
• Current treatments are not approved for non-AMD related GA, making accurate diagnosis vital.
• Research is ongoing to explore the efficacy of complement inhibitors in other retinal diseases.

Clinical Implications

Healthcare providers must utilize multimodal imaging techniques to confirm GA diagnosis and ensure appropriate treatment. Awareness of the potential for misdiagnosis is crucial, as current therapies are specific to AMD-related GA and may not be effective for other conditions.

Conclusion

Accurate identification of geographic atrophy is essential for effective treatment, particularly with the availability of new therapies. Ongoing research may expand treatment options for other retinal diseases in the future.

References

1. Haynes, J., Optometric Management, 2025 -- Geographic Atrophy: Early Detection and Patient Awareness Matters
2. Haynes, J., Optometric Management, 2025 -- Geographic Atrophy: Fact or Fiction
3. Haynes, J., Optometric Management, 2025 -- Identifying Geographic Atrophy Biomarkers
4. Oregon Health & Science University, Age-Related Macular Degeneration Preferred Practice Pattern®, 2025
5. ScienceDirect, Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration, 2023
6. optometric management — Detecting Diagnostic and Prognostic Biomarkers of Geographic Atrophy
7. Age-Related Macular Degeneration Preferred Practice Pattern® - Oregon Health & Science University
8. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials - ScienceDirect
9. New ReST Committee Report Published in JVRD Summarizes Analysis of Reported Cases of Retinal Vasculitis Following Syfovre Injection - The American Society of Retina Specialists